ClinicalTrials.gov
public full text
Public Domain
18F-FAPI and 18F-FDG PET/CT in Patients With Various Types of Cancer
FAP is overexpressed in the cancer-associated fibroblasts (CAFs) of 90% epithelial carcinomas. Currently, 68Ga-fibroblast activation protein inhibitor (FAPI) has shown promising diagnostic value in many types of tumors. However, there are currently no studies on head-to-head comparison of diagnosis value of various types of cancer in 18F-FAPI and 18F-FDG PET/CT. Therefore, we conducted a prospective study to investigate the value of 18F-FAPI PET/CT in various types of cancer, and compare it with 18F-FDG PET/CT.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers#1245066
- Evaluation Using FAPI-PET Targeting Cancer-associated Fibroblasts#1280499
- 68Ga-FAPI PET/CT in Malignant Tumors#843460
- Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma#1162986
- [68Ga]Ga-FAPI PET/CT in Gastric and Gastroesophageal Junctional Cancer#846033
Record · ID 1396732
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive